Skip to main content
. 2021 Sep 16;9(10):E1480–E1490. doi: 10.1055/a-1522-8723

Table 1. General characteristics of the population (n:312).

Sex (M/F) 133/179 (44.5 %/55.5 %)
Age (years) 13 (11–16)
Disease duration (months) 12 (6–18)
PCDAI 12.5 (5–22.5)
PCDAI < 10 (number) 132 (42.3 %)
PCDAI 10–30 (number) 155 (49.7 %)
PCDAI > 30 (number) 25 (8 %)
Hemoglobin (g/dL) 12 (11.1–12.5)
Serum albumin (g/dL) 3.9 (3.4–4.2)
C-reactive protein (mg/L) 5 (2–9)
Fecal calprotectin (μg/g) 250 (100–750)
Lewis score 600 (0–1350)
CECDAI 9 (0–15)
CE-CD score 14 (0–24)
Location (number) Before CE After CE

  • L1

 55 (17.6 %) 25 (8 %)

  • L1 + L4b

  0 (0 %) 29 (9.3 %)

  • L2

 39 (12.5 %) 23 (7.3 %)

  • L2 + L4b

  8 (2.6 %) 23 (7.3 %)

  • L3

 80 (25.6 %) 37 (12 %)

  • L3 + L4b

 45 (14.4 %) 77 (24.7 %)

  • L4b

 62 (19.9 %) 98 (31.4 %)

  • Unknown

 23 (7.5 %)  0 (0 %)
Therapy (single or in combination) (number) N

  • 5-aminosalicylic

  20

  • Methothrexate

  27

  • Azatiophrine

 100

  • Steroid

  33

  • Anti-TNF α (infliximab or adalimumab)

  99

  • Enteral nutrition

  27

  • None

  23

Data are expressed as number (percentage) or median (P25–75).

Location was assessed according to Paris classification.

PCDAI, Pediatric Crohn’s Disease Activity Index; CECDAI, Capsule Endoscopy Crohnʼs Disease Activity Index; CE-CD, capsule endoscopic Crohn’s disease.